title: Reversal of immune dysfunction in osteopetrotic rats by interferon-gamma: augmentation of macrophage Ia expression and lymphocyte interleukin-2 production and proliferation.
abstract: Lymphocytes from osteopetrotic (op) rats, compared to their normal (n) littermates, exhibit defective immune functions associated with their inability to resorb bone. Among these immune defects are the failure of their spleen cells to proliferate normally to mitogens and to generate IL-2. Addition of exogenous IL-2 failed to reverse the suppressed proliferation in the op spleen cells, indicating that additional defects were involved in the suppression. Phenotypic analysis of cellular constituents of op and n spleens revealed that the percentages of T cells, macrophages, and IL-2 receptor positive cells were not different. Furthermore, there was no difference in CD4 (W3/25) and CD8 (OX8) cells. However, the Ia+ (OX3) cells in the op spleen represented less than 50% of those found in the n spleen, but the op had higher levels of transferrin receptor (OX26). On the basis of the ability of interferon-gamma (IFN-gamma) to increase Ia expression, this cytokine was added to op spleen cells (10-50 U/ml) and found to increase the number of Ia+ cells to the level found in n spleen cells. Moreover, pretreatment of op spleen cells with IFN-gamma restored their ability to proliferate to mitogens and their responsiveness to IL-2. Not only did IFN-gamma reverse the defective response to IL-2, but it also augmented the defective IL-2 production by op spleen cells. Taken together, these findings demonstrate that IFN-gamma can reverse many of the impaired immune functions characteristic of op spleen cells in vitro. Furthermore, these data suggest that IFN-gamma may provide an important avenue of treatment in these animals that may contribute to restoration of normal bone resorption.
authors.affiliation: Cellular Immunology Section, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: N
authors.initials: N
authors.lastname: Hochman
authors.forename: H
authors.initials: H
authors.lastname: Hojo
authors.forename: S
authors.initials: S
authors.lastname: Hojo
authors.forename: M L
authors.initials: ML
authors.lastname: Corcoran
authors.forename: J B
authors.initials: JB
authors.lastname: Allen
authors.forename: C T
authors.initials: CT
authors.lastname: Hansen
authors.forename: S M
authors.initials: SM
authors.lastname: Wahl
authors.forename: L M
authors.initials: LM
authors.lastname: Wahl
mesh_terms: D000818:Animals; D001862:Bone Resorption; D003208:Concanavalin A / Q000494:pharmacology; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology*; D007375:Interleukin-1 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects*; D008264:Macrophages / Q000276:immunology*; D010022:Osteopetrosis / Q000276:immunology*; D051381:Rats; D011922:Rats, Mutant Strains; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013154:Spleen / Q000276:immunology
chemical_list: D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D007376:Interleukin-2; D008070:Lipopolysaccharides; D015375:Receptors, Interleukin-2; D003208:Concanavalin A; D007371:Interferon-gamma